



540 Gaither Road, Suite 400  
Rockville, Maryland 20850

August 1, 2024

**VIA EDGAR**

Division of Corporation Finance  
U.S. Securities and Exchange Commission  
100 F Street N.E.  
Washington, DC 20549

Attention: Lauren Hamill  
Alan Campbell  
Division of Corporation Finance  
Office of Life Sciences

**Re: Avalo Therapeutics, Inc.  
Registration Statement on Form S-3  
Filed June 6, 2024, as amended on July 11, 2024 and July 29,  
2024  
File No. 333-279992**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "Act"), Avalo Therapeutics, Inc. (the "Registrant") hereby requests that the U.S. Securities and Exchange Commission (the "Commission") take appropriate action to accelerate the effective date of the above-referenced registration statement (the "Registration Statement") so as to become effective on Monday, August 5, 2024, at 4:00 p.m. Eastern Time, or as soon thereafter as practicable.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Wyrick Robbins Yates & Ponton LLP, by calling Andrew Gibbons at (919) 781-4000. We also respectfully request that a copy of the written order from the Commission verifying the effective date and time of the Registration Statement be sent to Mr. Gibbons via email at [agibbons@wyrick.com](mailto:agibbons@wyrick.com).

Very truly yours,

AVALO THERAPEUTICS, INC.

By: /s/ Christopher Sullivan  
Chief Financial Officer

cc: Andrew Gibbons, Wyrick Robbins Yates & Ponton LLP